Thursday, July 12, 2012

Affymax (NASDAQ:AFFY) Leads Top Percentage Gainers on News of Supply Agreement for OMONTYS

Affymax (NASDAQ:AFFY) Leads Top Percentage Gainers on News of Supply Agreement for OMONTYSPalm Beach, FL 7/12/12 (StreetBeat) --, an investor research portal specializing in sector research including biotech and pharma stocks, issues an alert for Affymax, Inc. (Nasdaq: AFFY), trading at $13.30, gaining $1.34 or 11.20% as of 11:03AM EDT on over 1.5 Million shares. The stock had a morning high of $13.71 and is currently the top percentage gainer on the NASDAQ.

The Company today reported that Takeda Pharmaceuticals America, Inc. (TPA) has entered into a supply agreement for sourcing and supply of OMONTYS® (peginesatide) Injection to Fresenius Medical Care North America and certain of its affiliates. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population with chronic kidney disease (CKD) in the United States.

About Affymax, Inc. (Nasdaq: AFFY)
Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California. Affymax’s mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses. The company’s first marketed product, OMONTYS, was approved by the U.S. Food and Drug Administration (FDA) in March 2012.

About is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow on Twitter!/Investorideas
Follow on Facebook

Sign up for the free investor news and stock alerts at

Research biotech and pharma stocks at the Biotech stocks Directory

Become an Member

Follow on Twitter!/Investorideas
Follow on Facebook

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
800-665-0411 - Source –

Please contact for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

No comments:

Post a Comment